MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2020

    Sustained Improvement in Freezing of Gait (FOG) and Treatment Satisfaction at 12 months After Initiation of Carbidopa/Levodopa Enteral Suspension (CLES) in Advanced Parkinson’s Disease (APD) Patients in USA: Interim Results from the PROviDE Study

    R. Pahwa, S. Isaacson, B. Bluett, P. Kandukuri, N. Gupta, Y. Jalundhwala, P. Kukreja, I. Pan, J. Aldred (North Chicago, IL, USA)

    Objective: To evaluate the long-term effectiveness of CLES on FOG and treatment satisfaction in APD patients. Background: FOG, prevalent in about 60% of APD patients,…
  • MDS Virtual Congress 2020

    Linguistic Deficits in Patients with Parkinson’s Disease

    P. Akkunje, Y. Belur, R. Yadav, A. Rajasekaran, P. Yuvaraj, N. Kamble, S. Shivashankar, P. Pal (Bangalore, Karnataka, India)

    Objective: The objective of this study is to assess linguistic processing and production in patients with PD. Background: Parkinson's disease (PD) is a neurodegenerative condition…
  • MDS Virtual Congress 2020

    Implementation of the ParkinsonNet care concept shows better expertise and work satisfaction of health professionals, but improvement of multidisciplinary collaboration takes longer than one year

    I. Sturkenboom, M. Nijkrake, H. Woltjer, J. Fritz, A. Kaysen, M. Tiemessen, J. Kalf (Nijmegen, Netherlands)

    Objective: To evaluate the changes in perceived quality of care for people with Parkinson’s disease (PD) among health professionals (HPs) in Luxembourg at one year…
  • MDS Virtual Congress 2020

    SCA48: Ataxia Plus Chorea in a New Spanish Family

    M.I Gastón, G. Soriano, A. Alonso, S. Pasalodos, J. Salgado, M. Mendioroz (Pamplona, Spain)

    Objective: To describe a new family with Spinocerebellar Ataxia 48 (SCA48) characterized by ataxia and mild chorea as the most prominent initial symptoms as well…
  • MDS Virtual Congress 2020

    A Novel CACNA1A Nonsense Variant [c.6481C>G; (p.Arg2161Gly)] Causing Spino Cerebellar Ataxia Type 6 (SCA6)

    J.P Romero, J. Herreros, S. Santillán, Y. Moreno, A. Andújar (Madrid, Spain)

    Objective: To describe a new missense variant found in a 67 years old woman with progressive ataxia causing a phenotype compatible with SCA 6. Background:…
  • MDS Virtual Congress 2020

    Nivolumab-induced choreoathetosis in a woman with lung cancer – A case report with review of the literature

    J. Johansson Lindgren, M. Esbjörnsson, E. Tüzün, H. Griph, D. Van Westen, G. Sahin (Hässleholm, Sweden)

    Objective: To report an uncommon and severe neurological immune-related adverse event (nirAE) of nivolumab and to provide an overview of the current literature on nirAEs…
  • MDS Virtual Congress 2020

    Long-term safety and efficacy of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects: results of a Phase III study

    F. Pagan, A. Dekundy, M. Althaus, D. Mitsikostas (Washington, DC, USA)

    Objective: To assess the safety and efficacy of incobotulinumtoxinA for benign essential blepharospasm (BEB) in toxin-naïve subjects. Background: IncobotulinumtoxinA is efficacious for BEB. This was…
  • MDS Virtual Congress 2020

    New onset Tongue Tremor with Tacrolimus following Heart Transplantation

    E. Gray, K. Frei (Loma Linda, CA, USA)

    Objective: To report a case of tacrolimus induced tongue tremor. Background: Tongue tremor is uncommon and may present in isolation, as part of a syndrome,…
  • MDS Virtual Congress 2020

    Duration of Effect of IncobotulinumtoxinA for the Treatment of Blepharospasm in Botulinum Toxin-naïve Subjects: Results from a Phase III Study

    F. Pagan, A. Dekundy, M. Althaus, A. Scheschonka, J. Jankovic, D. Mitsikostas (Washington, DC, USA)

    Objective: The efficacy of incobotulinumtoxinA, a botulinum neurotoxin type A free from complexing proteins, was investigated in a randomized, placebo-controlled, prospective, Phase III study in…
  • MDS Virtual Congress 2020

    A Novel Variant of TUBB4A Dystonia (DYT4): A Case Report

    T. Lee, C. Goldin, D. Kern (Aurora, CO, USA)

    Objective: To describe the clinical presentation of a case of TUBB4A dystonia with a novel genetic variant Background: A missense variant at Arg2Gly in the…
  • « Previous Page
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • 149
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley